TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19852288
Drug: Levodopa dosage
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa dosage in groups C and E
Study: 15037889
Drug: 0.005% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% latanoprost instillation once daily in the morning
Study: 15037889
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol instillation twice daily
Study: 9687551
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (60 mg of oily solution of retinyl palmitate, 30 mg if aged <12 mo) every 6 mo
Study: 3141143
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/kg/d for those weighing less than 6 kg and 50 mg daily for those over 6 kg)
Study: 31898518
Drug: Ketogenic Diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic Diet (KD) with a restricted carbohydrate intake of 20-40 g/day
Study: 23842003
Drug: Hib vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib vaccination via vastus lateralis muscle (2 or 3 times at monthly intervals)
Study: 22216717
Drug: Carprofen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (all doses combined)
Study: 8985763
Drug: Concurrent control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent control (unintentionally not treated)
Study: 29077149
Drug: Routine drug
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drug therapy (Control)
Study: 25042302
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy plus topical analgesic
Study: 22313547
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment with venlafaxine xr 150 mg/day and supportive management (SM)
Study: 20049491
Drug: Gabapentin (GBT)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBT) 300 mg
Study: 20049491
Drug: Ropinirole (ROP)
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ropinirole (ROP) 0.5 mg
Study: 16293863
Drug: Epirubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin plus paclitaxel (EP) - epirubicin 75 mg/m2 and paclitaxel 200 mg/m2
Study: 8602382
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g 4 times/day
Study: 8602382
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at bedtime plus sucralfate 1 g 4 times/day
Study: 16696806
Drug: 300 mL
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mL white wine
Study: 16696806
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL beer
Study: 19809326
Drug: Lidocaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (100 mg)
Study: 27223128
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions, subgingival scaling and root planing
Study: 10454691
Drug: Nimodipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (60 mg taken orally every 4 hours)
Study: 10454691
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (6 g bolus and 2 g/hr intravenous infusion)
Study: 25596476
Drug: Maintenance tocolysis
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance tocolysis with nifedipine (exact dosage and duration not specified)
Study: 23663341
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of remifemin (one tablet twice daily) and paroxetine (20 mg once daily) for 2 months
Study: 23663341
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg once daily) for 2 months
Study: 18949459
Drug: Ketamine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (n = 19; mean ketamine blood plasma = 175.29 ng/mL)
Study: 9778002
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 ng/ml (group MF)
Study: 9778002
Drug: Fentanyl 15
Normalized name: fentaNYL 150 mcg/30 mL-D5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 15 ng/ml (group HF)
Study: 3280855
Drug: Aluminum-containing compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-containing compounds
Study: 27797282
Drug: Standard needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard needle injection
Study: 37868
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg)
Study: 31718254
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30 mg/day
Study: 22708519
Drug: Family drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family drug abstinence
Study: 20179658
Drug: Albuterol HFA
Normalized name: Albuterol Sulfate 0.09 MG/1 ACTUATION Inhalation Aerosol Powder [ALBUTEROL HFA]
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol HFA 180 microg
Study: 20179658
Drug: Albuterol HFA
Normalized name: Albuterol Sulfate 0.09 MG/1 ACTUATION Inhalation Aerosol Powder [ALBUTEROL HFA]
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol HFA 360 microg
Study: 17343553
Drug: Stimulant to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant to Atomoxetine switch
Study: 8646094
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose bupivacaine
Study: 1538159
Drug: rgp160 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rgp160 vaccine (40 micrograms, three doses on days 0, 30, and 180)
Study: 8817830
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (control)
Study: 1538159
Drug: Sera from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sera from HIV-1 antibody-negative volunteers (before vaccination)
Study: 18614736
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (15 mg Zn + 60 mg Fe + 250 microg folic acid)
Study: 18614736
Drug: Control (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (60 mg Fe + 250 microg folic acid)
Study: 31220365
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment for fracture risk
Study: 19652068
Drug: Chlorambucil 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil 0.8 mg/kg orally on days 1 and 15, repeated every 4 weeks for a maximum of six cycles.
Study: 20926522
Drug: Treatment (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (not specified)
Study: 17472863
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch
Study: 11417777
Drug: Inhaled nicotine
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nicotine
Study: 2544254
Drug: Central parenteral
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central parenteral nutrition (CPN)
Study: 31209560
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A supplementation (10,000 IU/dose; n=98)
Study: 28506228
Drug: Pulian ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulian ointment
Study: 12656905
Drug: Cinnoxicam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnoxicam (30 mg suppository every 4 days for 12 months)
Study: 12656905
Drug: Placebo (glycerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glycerine suppository every 4 days for 12 months)
Study: 8625641
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no availability of daily itemized patient charges)
Study: 6377610
Drug: Other factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other factors (blood transfusion, preformed antibodies, graft number, recipient sex)
Study: 25072976
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (general wrapping)
Study: 20622362
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation (Cisplatinum 40 mg/m2 and 5 Fluorouracil 500 mg/m2 continuous infusions with radiotherapy on D2-D5 in first and last 5 sessions of radiation therapy)
Study: 20622362
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Concurrent chemoradiation and Control)
Study: 12372041
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose tacrolimus (trough 5-10 ng/mL)
Study: 9522106
Drug: System I
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: System I (investigational testosterone transdermal system)
Study: 7652966
Drug: No thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thrombolytic therapy (Control)
Study: 2540099
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory agents (NSAIA)
Study: 24943252
Drug: Adaptive Iterative
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive Iterative Dose Reduction (AIDR) 3D
Study: 30095550
Drug: Ketamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.4 mg/kg)
Study: 8737615
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol
Study: 16827813
Drug: R216073 (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: R216073 (2,000 mg)
Study: 1400057
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including ibuprofen, pentoxifylline, and control)
Study: 22492565
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural self‐help treatment (online)
Study: 20817794
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg daily for 3 months (after initial atorvastatin or placebo)
Study: 7552591
Drug: 50 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg/kg loading dose of diamorphine
Study: 7552591
Drug: 200 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg/kg loading dose of diamorphine
Study: 3065875
Drug: Dydrogesterone 10
Normalized name: dydrogesterone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone 10 mg twice daily from the 12th day until onset of the following menstrual period
Study: 25853384
Drug: Cervical administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical administration of radiocolloid and blue dye (Group 1)
Study: 20593635
Drug: Adjunctive Periochip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Periochip (chlorhexidine) with scaling and root planing
Study: 9776411
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg/alternate days
Study: 7531109
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg twice daily for 3 days)
Study: 12189744
Drug: Permixon 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permixon 320 mg per day
Study: 12189744
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg per day
Study: 18783114
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with an infrared laser (830nm, 500mW, 20s, 4J/point), once a week for four consecutive weeks.
Study: 18783114
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, once a week for four consecutive weeks.
Study: 10442192
Drug: Cisplatin with
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin with amifostine (740 mg/m2)
Study: 30939592
Drug: d-methadone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-methadone (single doses up to 150 mg)
Study: 30939592
Drug: d-methadone (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-methadone (daily doses up to 75 mg for 10 days)
Study: 30939592
Drug: d-methadone (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-methadone (higher doses)
Study: 30939592
Drug: d-methadone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-methadone (60 mg or above)
Study: 25607118
Drug: LifeWave Energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LifeWave Energy Enhancer (LEE) patches
Study: 21681064
Drug: TreSPE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TreSPE treatment (treadmill training, stretching, respiratory, and proprioceptive exercise) twice a week for 8 weeks
Study: 21681064
Drug: TreSPE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TreSPE treatment
Study: 19224764
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with procarbazine, lomustine, and vincristine
Study: 14568832
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser pretreatment plus 4% lidocaine cream
Study: 28950157
Drug: Group-based multicomponent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based multicomponent treatment (GMT)
Study: 24813065
Drug: L-methylfolate 15
Normalized name: L-METHYLFOLATE 15MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-methylfolate 15 mg/d for 60 days
Study: 22914396
Drug: Pessary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pessary therapy
Study: 17067621
Drug: Mason-Likar (ML)
Normalized name: Oncorhynchus masou sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mason-Likar (ML) 12-lead ECG
Study: 9728982
Drug: Heparin-coated stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stent implantation
Study: 3276642
Drug: No shampoos,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No shampoos, surgical preparation with chlorhexidine
Study: 3276642
Drug: Shampoos with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shampoos with iodophor, surgical preparation with iodophor
Study: 3276642
Drug: No shampoos,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No shampoos, surgical preparation with iodophor
Study: 31308263
Drug: Bilateral ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided transmuscular quadratus lumborum block with 30 mL ropivacaine 0.375%
Study: 29097935
Drug: Individualized contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized contrast medium injection protocol (G1)
Study: 29097935
Drug: Standard contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard contrast medium injection (G2)
Study: 12660683
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 4 mg
Study: 1703611
Drug: ANP (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP (0.1 mg i.v. as a bolus)
Study: 124394
Drug: Perforated cellophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perforated cellophane dressing without additional medication
Study: 30668833
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline catheter lock solution (NSCLS)
Study: 26368824
Drug: MRK Ad5
Normalized name: mirikizumab-mrkz
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRK Ad5 gag/pol/nef subtype B HIV‐1 preventive vaccine
Study: 24140372
Drug: Heparin-coated foldable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated foldable intraocular lens (Polylens EC‐1YH PAL)
Study: 9753234
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for eight weeks + Rebamipide 300 mg three times a day for eight weeks (group OR)
Study: 9753234
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for eight weeks + Amoxicillin 1500 mg three times a day for the first two weeks (group OA)
Study: 7992465
Drug: Casodex (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex (50 mg daily)
Study: 3416419
Drug: Allerglobuline (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allerglobuline (10% human immunoglobulin preparation of placental origin)
Study: 3416419
Drug: Placebo (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10% human albumin solution)
Study: 18301905
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection (control)
Study: 28202842
Drug: 10 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/d of trehalose
Study: 20387996
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg EPs 7630 tablets three times a day (30‐mg group)
Study: 17914002
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement interventions (education and resources for medication management or psychotherapy) for 6 to 12 months
Study: 1806376
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg b.i.d.
Study: 27435979
Drug: LY2940094 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2940094 (40 mg/d)
Study: 24216403
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (1.5‐mg/kg bolus followed by 2‐mg/kg/h infusion)
Study: 12085075
Drug: Eye patch
Normalized name: eye patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye patch
Study: 12085075
Drug: No eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: No eye patch
Study: 8678249
Drug: Propofol (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (starting with 9 mg.kg‐1 h‐1, reducing to 6 mg.kg‐1 h‐1 after 20 min)
Study: 8142195
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg twice daily)
Study: 398483
Drug: Amoxycillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (250 mg every 8 hours for 7 to 10 days)
Study: 31782656
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help (low-intensity cognitive behaviour therapy including behavioural activation)
Study: 15140756
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement (GHR)
Study: 11236299
Drug: Becotide (innovator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Becotide (innovator formulation)
Study: 11236299
Drug: Beclate (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclate (generic formulation)
Study: 2031258
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg daily for 14 days
Study: 6294175
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily (open treatment)
Study: 30523522
Drug: Paliperidone Palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone Palmitate (PP1M) (50-150 mg equivalent)
Study: 30523522
Drug: Oral Paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Paliperidone Extended Release (ER) (6-12 mg/day)
Study: 25277322
Drug: Solid lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid lipid curcumin (400 mg as Longvida)
Study: 18069576
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of perindopril and indapamide
Study: 12373472
Drug: Enoximone (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (initial bolus 0.5 mg/kg followed by continuous infusion of 2.5 micro g/kg per minute until the 2nd postoperative day)
Study: 22270468
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of 160 mL of levobupivacaine with adrenaline
Study: 15704481
Drug: Phezam treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phezam treatment for 8 weeks
Study: 11833047
Drug: Phytosterol ester-enriched
Normalized name: phytosterol esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol ester-enriched margarine (20 g/d, 1.82 g/d of phytosterols)
Study: 22699924
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of IV furosemide
Study: 22699924
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion of IV furosemide
Study: 20678688
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of esomeprazole 40 mg
Study: 20678688
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of test and reference formulations
Study: 12201829
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (continuous for 9 years)
Study: 12201829
Drug: No GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GH replacement therapy
Study: 7521636
Drug: APDT vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APDT vaccines (liquid and freeze-dried)